The carcinogenicity of inhalation exposure to antimony was investigated in rats. Wistar-rats were exposed by inhalation to 45 milligrams per cubic meter (mg/m3) antimony-oxide, 40mg/m3 antimony ore, or filtered air 7 hours per day, 5 days per week for 52 weeks. Five rats/sex/group were sacrificed at 6, 9 and 12 months, the rest at 20 weeks post exposure. Autopsies and histopathological examinations were performed on all animals. Tissues were analyzed for antimony, arsenic (7440382), and other inorganic elements by atomic absorption and proton induced X-ray emission. At 9 months, antimony in lungs of rats exposed to antimony-oxide was 5.4 to 5.7 times greater in males and females, and arsenic was 21 and 10.8 times greater, than in these respective groups exposed to antimony ore. Other tissues from females contained more arsenic than the same tissues from males. At final sacrifice, lungs from both exposure groups contained slightly elevated, confluent, white and yellow foci on the pleural surfaces of all lobes. Post exposure, alveolar particles were significantly decreased, but interstitial fibrosis continued to increase, affecting as much as 80 percent of the alveoli. No lung tumors were seen in control rats of either sex or in male rats exposed to either compound. Both antimony-oxide and ore exposed females developed lung neoplasms, the first lung tumor being seen after 41 weeks exposure to antimony ore or 53 weeks antimony-oxide exposure. Lung tumors were found in 27 percent of antimony-oxide exposed animals and 25 percent of those exposed to ore. Tumor types included squamous cell carcinomas, bronchoalveolar adenomas, bronchoalveolar carcinomas and scirrhous carcinomas. Multiple tumors were seen in six oxide and three ore exposed female rats. Both controls and exposed animals also developed a variety of tumors typical of this rat strain. The authors conclude that female rats are more susceptible to lung cancer induction by antimony-oxide and antimony ore than males. The significance of increased pulmonary arsenic concentrations is not clear.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.